Skip to search formSkip to main contentSkip to account menu

quelamycin

Known as: triferric doxorubicin 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Doxorubicin

Narrower (1)

NSC-267703
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Iron Supplementation: What's New?
Supplemental orally-administered iron has been available for centuries, but parenteral administration of iron as a therapeutic… 
2012
2012
Abstract 4611: Cancer reversal by dual strategy: A new molecular target?
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Haste is a bad counselor when one is striving to… 
1981
1981
Neurotoxicity of quelamycin in the rat.
: Male Sprague-Dawley rats were given a single dose of 10 or 20 mg/kg quelamycin intravenously and perfusion fixed at 4, 12, 28… 
1981
1981
Neurotoxicity of quelamycin in the rat.
Male Sprague-Dawley rats were given a single dose of 10 or 20 mg/kg quelamycin intravenously and perfusion fixed at 4, 12, 28 and… 
1980
1980
Quelamycin: a summary of phase I clinical trials.
Quelamycin is triferric doxorubicin, a metallic derivative of adriamycin which, in experimental studies, has been found to have a… 
1979
1979
Early clinical trial with quelamycin.
Quelamycin (triferric doxorubicin) is a derivative of Adriamycin with different pharmacologic properties. Our phase I clinical… 
1979
1979
Iron toxicity studies of quelamycin.
A previous phase I study demonstrated excessive generalized toxicity (20 of 21 patients) and cardiotoxicity (eight of 21 patients… 
Highly Cited
1978
Highly Cited
1978
Quelamycin, a new derivative of adriamycin with several possible therapeutic advantages.
1978
1978
Phase I clinical study of quelamycin.
A phase I clinical study was done with quelamycin, a recently synthesized triferric derivative of adriamycin. Twenty-one good… 
1978
1978
Preliminary evaluation of a phase I clinical study of quelamycin.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)